Biotech News

Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686

Gain Therapeutics (GANX)Gain TherapeuticsConference / presentation

IAPRD late-breaking poster shows MDS-UPDRS motor scores remained stable compared to baseline recorded at study entry with no disease progression among the 13 evaluable participants who completed 12 months of daily oral administration of rexaceract

Related news

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

CGTXCognition Therapeutics2026-11-09 12:30 EST

Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference

VYGRVoyager Therapeutics2026-10-27 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026

ANLAdlai Nortye Ltd.2026-10-27 20:05 EST

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

HRMYHarmony Biosciences2026-10-01 12:05 EST

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

VTGNVistagen Therapeutics, Inc.2026-09-10 12:30 EST

Vistagen to Present at Psych Congress 2026

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

Gain Therapeutics

Allosteric Small-Molecule Platform Gain Therapeutics uses its Magellan discovery platform to identify allosteric small molecules that restore the function of disease-associated proteins. Its lead efforts focus on neurodegenerative disorders. GT-02287 GT-02287 is an oral, brain-penetrant modulator of glucocerebrosidase being developed for...

Recent company news

Stock data

Close
1.05 USD
Market cap
78.06M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States